Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2014
Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01218802 (Randomized Placebo-controlled Trial of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risk and Inflammation), which is not on this map. Cited by 103 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Placebo-controlled Trial of Rosuvastatin in HIV-Infected Subjects to Modulate Cardiovascular Risk and Inflammation
Who cites it
103 citing papers in PubMed, 1 synthesis or guideline pooled it, 146 citations in OpenAlex.
- A Systematic Review and Meta-Analysis on the Impact of Statin Treatment in HIV Patients on Antiretroviral Therapy.International journal of environmental research and public health · 2023Pooled it
- Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Trial
- Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis.The lancet. HIV · 2026 · on this mapTrial
- Trial
- A Randomized, Placebo-Controlled, Pilot Clinical Trial of Dipyridamole to Decrease Human Immunodeficiency Virus-Associated Chronic Inflammation.The Journal of infectious diseases · 2020Trial
- Trial
- Statin effect on coronary calcium distribution, mass and volume scores and associations with immune activation among HIV+ persons on antiretroviral therapy.Antiviral therapy · 2020Trial
- Brief Report: Zinc Supplementation and Inflammation in Treated HIV.Journal of acquired immune deficiency syndromes (1999) · 2019Trial
- Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study.Journal of the International AIDS Society · 2019Trial
- Statin Therapy Does Not Reduce Liver Fat Scores in Patients Receiving Antiretroviral Therapy for HIV Infection.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2019Trial
- Novel mediators of statin effects on plaque in HIV: a proteomics approach.AIDS (London, England) · 2018Trial
- Short Communication: The Effect of Rosuvastatin on Vascular Disease Differs by Smoking Status in Treated HIV Infection.AIDS research and human retroviruses · 2018Trial
- Effect of statin on arginine metabolites in treated HIV-infection.Atherosclerosis · 2017Trial
- Baseline Vitamin D Deficiency Decreases the Effectiveness of Statins in HIV-Infected Adults on Antiretroviral Therapy.Journal of acquired immune deficiency syndromes (1999) · 2017Trial
- Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV.AIDS (London, England) · 2017Trial
- Incidental findings on chest computed tomography are common and linked to inflammation in HIV-infected adults.Antiviral therapy · 2017Trial
- Rosuvastatin slows progression of subclinical atherosclerosis in patients with treated HIV infection.AIDS (London, England) · 2016Trial
- Effects of 96 Weeks of Rosuvastatin on Bone, Muscle, and Fat in HIV-Infected Adults on Effective Antiretroviral Therapy.AIDS research and human retroviruses · 2016Trial
- Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV.AIDS (London, England) · 2016Trial
- The effect of physical activity on cardiometabolic health and inflammation in treated HIV infection.Antiviral therapy · 2016Trial
43 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundStatins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, have anti-inflammatory effects that are independent of their lipid-lowering properties. Despite suppressive antiretroviral therapy (ART), elevated levels of immune activation and inflammation often persist.
methodsThe Stopping Atherosclerosis and Treating Unhealthy Bone With Rosuvastatin in HIV (SATURN-HIV) trial is a randomized, double-blind, placebo-controlled study, designed to investigate the effects of rosuvastatin (10 mg/daily) on markers of cardiovascular disease risk in ART-treated human immunodeficiency virus (HIV)-infected subjects. A preplanned analysis was to assess changes in markers of immune activation at week 24. Subjects with low-density lipoprotein cholesterol <130 mg/dL and heightened immune activation (%CD8(+)CD38(+)HLA-DR(+) ≥19%, or plasma high-sensitivity C-reactive protein ≥2 mg/L) were randomized to receive rosuvastatin or placebo. We measured plasma (soluble CD14 and CD163) and cellular markers of monocyte activation (proportions of monocyte subsets and tissue factor expression) and T-cell activation (expression of CD38, HLA-DR, and PD1).
resultsAfter 24 weeks of rosuvastatin, we found significant decreases in plasma levels of soluble CD14 (-13.4% vs 1.2%, P = .002) and in proportions of tissue factor-positive patrolling (CD14(Dim)CD16(+)) monocytes (-38.8% vs -11.9%, P = .04) in rosuvastatin-treated vs placebo-treated subjects. These findings were independent of the lipid-lowering effect and the use of protease inhibitors. Rosuvastatin did not lead to any changes in levels of T-cell activation.
conclusionsRosuvastatin treatment effectively lowered markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. CLINICAL TRIALS REGISTRATION: NCT01218802.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.